Tirzepatide (Zepbound) for Sleep Apnea

Sleep · §197

The first drug ever approved for sleep apnea isn't a sleep drug. It's a weekly injection that produces large, sustained weight loss — and because obesity drives most severe sleep apnea, treating the weight treats the apnea too. Over a year on it, about half of people end up with their sleep tests close to normal, lose around a fifth of their body weight, and drop their blood pressure 7 to 9 points. The catch isn't subtle: roughly $12,000 a year at full price, the gains reverse when you stop, and a CPAP mask — the pressurised mask worn at night — is still a more direct fix for the patient who tolerates one. What follows is when this makes sense, when it doesn't, and what a year on it actually looks like.

Decide · Weekly Evidence Moderate Chapter Sleep

For the adult who's overweight and stops breathing dozens of times an hour at night, this is the first injection-or-pill option that actually moves the needle. In two large year-long trials, about half ended up with their sleep tests close to normal, lost roughly a fifth of their body weight, and saw blood pressure and inflammation drop along the way. The price tag is real and the commitment is permanent — but for the millions who refuse the mask, there wasn't a serious alternative until now.

Sleep apnea in adults is mostly an obesity story. Fat builds up around the throat and inside the tongue itself; lying down, the airway narrows and the back of the tongue collapses against the throat wall dozens of times an hour. Take enough weight off and the airway opens up — imaging studies have shown that the apnea-hypopnea index falls in proportion to how much tongue fat the weight loss takes with it Wang 2020. That's the lever tirzepatide pulls — not on the breathing muscles directly, but on the fat that crowds them. A weekly injection produces the kind of body-composition change that a year of strict dieting would, if anyone actually held to one Jastreboff 2022, and the apnea follows the weight down Schwartz 2008.

How well it works

Two trials, one year each, 469 adults with severe sleep apnea — averaging around fifty breathing pauses an hour and a BMI of 39. Half were already using a CPAP mask; the other half weren't. On full-dose tirzepatide, breathing pauses fell by 25 to 29 events an hour while placebo barely moved. About half the people on the drug ended the year below mild-apnea cutoffs, with daytime alertness scores in the normal range. Systolic blood pressure dropped 7 to 9 points; an inflammation marker called hsCRP fell by about a third.

The size of the effect is what earned the FDA's December 2024 approval — the first drug ever cleared for sleep apnea FDA 2024. A 2024 review of every drug ever tested for sleep apnea put tirzepatide and its drug class on top by a wide margin Sun 2024. None of this came as a surprise to anyone who'd been watching the older behavioural-weight-loss data, where lifestyle programmes that produced even modest weight loss in people with diabetes nudged apnea down too Foster 2009; tirzepatide just produces vastly more weight loss than any lifestyle programme has managed.

What years of untreated apnea actually do

Stopping breathing for ten seconds at a time, dozens of times a night, isn't a tiredness problem with a fix you keep meaning to get to. Across two decades, severe untreated sleep apnea roughly doubles the odds of dying — mostly through cardiovascular damage that builds quietly in the background Young 2008. The story shows up at every scale. The morning headache you blame on dehydration. The two-o'clock meeting that's a fight to stay awake. The partner who used to find the snoring funny and now lies awake counting the long silences in between. The drive home where you don't quite remember the last few miles. Years in, the bill arrives: blood pressure that won't come down on the third drug your doctor adds, atrial fibrillation, a thickened heart wall on the next echo, sometimes a stroke. About fifteen percent of middle-aged men and five percent of middle-aged women have moderate-to-severe apnea, and most of them have no idea they do Peppard 2013.

What taking it looks like

A small pen autoinjector, once a week, into the belly, thigh, or upper arm. Refrigerator storage between doses. You don't start at the target dose — you titrate up over months. Most of the side effects ride the titration window; once the dose has been steady for a few weeks, the body usually adjusts by month three or four.

When this is the wrong drug

The boxed warning is the bright line: don't take it if you or a close relative have ever had medullary thyroid cancer or the inherited condition called multiple endocrine neoplasia type 2. Pregnancy and breastfeeding are off; the manufacturer recommends stopping at least two months before trying to conceive. If you're already on insulin or one of the older diabetes pills called sulfonylureas, combining without dose reduction drops blood sugar dangerously low. Active or unresolved eating-disorder history is a hard no — rapid weight-loss drugs and disordered eating are a known bad combination.

Versus the alternatives

The CPAP mask is still the most direct treatment for obstructive sleep apnea. When people actually wear it more than four hours a night, on most nights, it almost completely normalises breathing and restores daytime alertness AASM 2019. The catch sits in that first clause. Real-world adherence is famously poor — roughly a third to half of people abandon CPAP within a year Weaver 2007. The biggest trial of CPAP for preventing heart attacks came back null, mostly because participants couldn't keep the mask on long enough each night to test the question fairly McEvoy 2016. For the patient who wears a mask well, CPAP is still more direct, more rapid, and far cheaper than the drug.

For the patient who can't or won't — and that's most of them — the realistic options before now were a custom mouthpiece that pulls the jaw forward (modest improvement), throat or jaw surgery (mixed results), an implanted nerve stimulator that nudges the tongue forward during sleep (a serious procedure with narrow eligibility), or bariatric surgery (the biggest non-drug effect on apnea, but a permanent anatomic change). Tirzepatide is the first medication with an effect that beats most of these. It hasn't been compared directly to CPAP in a trial — but for the patient who's already failed to wear one, that comparison is moot.

Where it goes wrong

Two failure modes dominate. The first is the first three months. Nausea hits about a quarter of people; vomiting and diarrhea closer to a sixth. A small fraction — roughly one in twenty — quit the drug because of it. Slowing the titration, injecting before bed, eating smaller meals, and short courses of anti-nausea medication carry most people through.

The second matters more: stopping the drug. The closest cousin study, of the related drug semaglutide, showed that two-thirds of the weight comes back within a year off the drug, with blood pressure and the metabolic gains tracking back up in parallel Wilding 2022. The expectation for tirzepatide is the same: stop, and the weight returns, and the sleep apnea comes back with it. No lower maintenance dose has been proven to hold the gains at a lower cost. The most common mistake people make planning around this drug is treating it as a finite course. It isn't.

What it costs and how to get it

US list price runs about $1,000 to $1,350 a month. Without coverage, around $12,000 to $16,000 a year. Insurance has been the binding constraint — many commercial plans excluded the drug when it was prescribed for weight loss alone, and Medicare by law cannot pay for weight-loss medication. The new sleep apnea indication potentially changes that math: a prescription coded for sleep apnea is a medical-necessity claim, and several large payers, plus Medicare specifically for the sleep apnea indication, have signalled coverage. The path is usually a documented sleep study, a body mass index of 30 or higher, and a prior-authorisation form. Manufacturer savings cards can bring out-of-pocket as low as $25 a month for people with commercial insurance, but the cards have caps and expire. Supply was tight through 2023 and into 2024; that's eased but isn't fully resolved.

What the noise around this drug gets wrong

Three common misreads. First, that it's a sleep drug. It isn't — it's a weight-loss drug whose effect on sleep apnea runs through the weight loss. People who have sleep apnea but aren't carrying extra weight aren't the population this is for. Second, that it replaces CPAP. The trial didn't test that and the FDA's label doesn't say it. A person who tolerates a CPAP mask well is still better off using one. Third, that it's a treatment with a finish line. There is no taper protocol that holds the gains; the drug works for as long as you take it and not after.

What changes if you start, and when

Month one is mostly tolerating the side effects. By month three the scale has moved 5 to 8 percent and clothes don't fit. By month six you're into double-digit weight loss; people who haven't seen you for a season do a double-take. The bedroom gets quieter — the partner who used to wake you to roll over stops doing it. Blood pressure at the next visit is meaningfully lower, and the doctor mentions cutting back one of the pills. A repeat sleep study somewhere between month nine and a year typically shows the breathing pauses halved or more, often well inside mild or normal range Malhotra 2024. The thing you stopped noticing because you'd lived with it for years — the afternoon you used to claw through — quietly stops happening. Whether the drug also adds years onto the back end of your life isn't fully proven for tirzepatide specifically yet, but every comparable signal so far has come in positive — major cardiovascular events fell by roughly a fifth on the related drug semaglutide in adults with obesity Lincoff 2023, and a pre-specified review of tirzepatide's cardiovascular signal found no excess risk, with the trend favouring the drug Sattar 2022.

Adjacent topics worth knowing about

For the broader sleep apnea picture: how the diagnosis is actually made, the difference between obstructive and central apnea, the at-home sleep study versus the in-lab one, and where positional therapy and the jaw-forward mouthpieces fit. For the weight-loss side: the broader drug class that tirzepatide belongs to, bariatric surgery as an alternative anatomic intervention, and the natural-history question of whether substantial weight loss by any route produces the same apnea reversal. For the cardiovascular question: blood pressure thresholds worth caring about, ApoB testing as a sharper risk number than LDL cholesterol, and the role of inflammation markers like hsCRP.

Related in the handbook

Helps

— This drug treats apnea by treating the weight that drives it — an option for people who won't tolerate a CPAP mask.

— Tirzepatide is part of the same incretin-drug class whose benefits reach well past weight loss.
— A year of this much weight loss costs muscle and bone too — protein and lifting protect them.
— The same drug approved for sleep apnea is a frontline type 2 diabetes medicine. One injection can work both problems.
— Weight-driven airway crowding underlies both full apnea and its milder cousin, upper-airway resistance.

Substance and claimed effects

Tirzepatide is a once-weekly subcutaneous peptide that activates both the GIP and GLP-1 incretin receptors. It was first approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). In December 2024 the FDA approved it as the first pharmacotherapy specifically for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity FDA 2024. The entry covers the substance and its consequences in this population: reduction of apnea-hypopnea index (AHI), weight loss, daytime sleepiness, blood pressure, inflammation, cardiometabolic risk markers, plus the burden side — adverse events, cost, the discontinuation problem.

Evidence by addressing question

Mechanism

Obesity and OSA are mechanistically coupled. Adipose tissue around the pharynx — parapharyngeal fat pads, soft palate, and tongue — narrows the upper airway and increases collapsibility during sleep Schwartz 2008. Reduced lung volume in supine obesity decreases caudal traction on the airway, further raising collapsibility. MRI work has shown that tongue fat specifically is an independent driver of OSA severity and that weight loss reduces tongue fat in proportion to overall fat loss; the magnitude of AHI improvement after weight loss tracks tongue-fat reduction more closely than overall BMI change Wang 2020.

Tirzepatide's relevant mechanism in OSA is therefore indirect: it produces large, sustained weight loss (≈20% of body weight at one year), which reduces upper-airway fat, increases lung volume, and lowers airway collapsibility. There is no evidence for a direct neuromuscular effect on upper-airway dilator tone, and the SURMOUNT-OSA trials did not test one. Independent of weight, GIP/GLP-1 coagonism reduces systemic inflammation (hsCRP), blood pressure, and visceral adiposity — pathways that matter for the cardiovascular complications of OSA even before AHI improves.

Evidence

The pivotal evidence is SURMOUNT-OSA, two parallel 52-week, double-blind, placebo-controlled randomized trials reported as a single NEJM publication Malhotra 2024. The trials enrolled 469 adults with moderate-to-severe OSA (AHI ≥15) and obesity (BMI ≥30). Trial 1 enrolled participants not using positive airway pressure (PAP); Trial 2 enrolled participants on established PAP therapy. Both used the maximum tolerated dose of tirzepatide (10 or 15 mg weekly) versus placebo.

Baseline characteristics were severe: mean AHI ≈50 events/hour, mean BMI ≈39 kg/m², ~70% male, mean age ~50. At 52 weeks:

AHI: Trial 1, mean change −25.3 events/hour with tirzepatide vs −5.3 with placebo (between-group difference −20.0, 95% CI −25.8 to −14.2). Trial 2, −29.3 vs −5.5 (difference −23.8, 95% CI −29.6 to −17.9). Both p<0.001.
Composite disease resolution (AHI <5, or AHI <15 with normalized Epworth Sleepiness Score): ~50% of tirzepatide arms in both trials, vs ~14% on placebo.
Body weight: −17.7% (Trial 1) and −19.6% (Trial 2) vs ~−1.6% placebo.
Hypoxic burden and sleep apnea-specific hypoxic burden: reduced ~40% from baseline in tirzepatide arms.
Patient-reported sleep impairment (PROMIS-SD) and daytime sleepiness: significantly improved in tirzepatide arms; the daytime-sleepiness effect was more pronounced in Trial 2 (PAP-experienced cohort), where baseline Epworth scores were higher.
Systolic blood pressure: ~−7 to −9 mmHg in tirzepatide arms.
hsCRP: reduced ~35%.

The AHI effect was clinically large — a baseline-severe-OSA population had mean post-treatment AHI consistent with mild OSA or normal. The effect on daytime sleepiness was modest in absolute terms (~1.3-point Epworth reduction vs placebo) but is plausibly underestimated because participants without PAP already had near-normal Epworth scores at entry.

Supporting evidence: behavioural weight loss of comparable magnitude in the Sleep AHEAD trial (T2D + obesity) reduced AHI by ~5 events/hour at one year and produced higher OSA remission rates than diabetes support alone Foster 2009. That establishes weight loss as the lever — tirzepatide simply produces far larger and more sustained weight loss than behavioural programmes Jastreboff 2022.

A 2024 network meta-analysis comparing pharmacotherapies for OSA placed GLP-1/GIP agonists as the largest AHI-reducing agents tested to date, ahead of selective noradrenergic-cholinergic combinations Sun 2024.

Protocol

Subcutaneous injection, once weekly. Standard titration: 2.5 mg weekly for 4 weeks, then 5 mg for 4 weeks, with monthly 2.5 mg increments to a maintenance dose of 10 mg or 15 mg as tolerated. Sites: abdomen, thigh, or upper arm. The SURMOUNT-OSA protocol used the maximum tolerated dose (10 or 15 mg); both produced the AHI effect, with the 15 mg arm showing slightly greater weight loss but no clear separation on AHI. Effect onset on AHI is gradual and roughly tracks weight loss; benefit at 24 weeks is meaningful but full effect requires ~52 weeks of treatment. Persistence requires indefinite use — see discontinuation under failure-modes.

Contraindications

Boxed warning: medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN 2). Tirzepatide caused dose-dependent thyroid C-cell tumors in rodent studies; human relevance is unknown but the contraindication is absolute for personal or family history. Other contraindications and cautions:

Prior serious hypersensitivity to tirzepatide.
Pregnancy and breastfeeding — animal reproductive toxicity; no human safety data; manufacturer recommends discontinuation ≥2 months before conception.
History of pancreatitis — relative contraindication; rare cases of acute pancreatitis reported in SURMOUNT and SURPASS programmes.
Severe gastrointestinal disease (gastroparesis, severe IBD) — drug delays gastric emptying.
Active or historical eating disorders — rapid weight-loss agents are contraindicated in active anorexia/bulimia and should be used cautiously in any binge-eating spectrum.
Concomitant insulin or sulfonylureas — additive hypoglycemia risk; dose reduction of the secretagogue/insulin typically required.
Severe renal impairment — caution due to volume-depletion risk from GI side effects.
Diabetic retinopathy — monitor; rapid glycemic improvement has been associated with retinopathy progression with other agents.

Adverse events / failure-modes

SURMOUNT-OSA adverse-event profile mirrors the broader tirzepatide programme: predominantly gastrointestinal, dose- and titration-dependent. Most common: nausea (~25–30%), diarrhea (~15–20%), constipation, vomiting, dyspepsia, eructation. GI events are usually mild-to-moderate, peak during titration, and attenuate over months. Discontinuation due to adverse events was ~5% in SURMOUNT-OSA, similar to obesity trials. Injection-site reactions occur but are typically minor.

Rarer signals: acute pancreatitis (low absolute incidence; signal not clearly elevated vs placebo across the programme), cholelithiasis and cholecystitis (rapid weight loss is a known driver of gallstones regardless of agent), acute kidney injury (almost always secondary to dehydration from GI symptoms), and very rare reports of bowel obstruction or ileus tied to delayed gastric emptying. SURPASS-CVOT data and a pre-specified cardiovascular meta-analysis showed no excess of major adverse cardiovascular events; if anything, a non-significant signal favoring tirzepatide Sattar 2022.

The clinically most important failure-mode is discontinuation. The STEP 1 extension showed that two-thirds of semaglutide-induced weight loss is regained within a year of stopping, with cardiometabolic improvements reverting in parallel Wilding 2022. The expectation for tirzepatide is the same: stop the drug and OSA returns as weight returns. The drug is a chronic therapy, not a course.

Alternatives

The current standard of care for moderate-to-severe OSA is positive airway pressure (PAP), almost always continuous PAP (CPAP). When tolerated and used >4 h/night for >5 nights/week, CPAP reliably normalizes AHI and improves sleepiness AASM 2019. The catch is adherence: ~30–50% of patients abandon CPAP within a year, and average usage in real-world cohorts is well below the therapeutic threshold Weaver 2007. The SAVE trial of CPAP for cardiovascular event prevention in OSA was famously null — partly because mean CPAP usage was 3.3 h/night, well below the threshold where downstream effects are seen McEvoy 2016.

Other alternatives: oral mandibular advancement devices (modest AHI reduction; better tolerated than CPAP), upper-airway surgery (UPPP, maxillomandibular advancement), hypoglossal-nerve stimulation (Inspire — implant, expensive, narrow eligibility), positional therapy for positional OSA, and weight loss by other means (bariatric surgery has the largest non-pharmacologic AHI effect). Tirzepatide is the first medication with a direct OSA indication; it does not replace CPAP head-to-head and was not compared to CPAP in SURMOUNT-OSA. The clinical positioning is as monotherapy when PAP is refused or not tolerated, or as add-on to PAP for weight loss and cardiometabolic benefit.

Stakes

Untreated moderate-to-severe OSA roughly doubles all-cause mortality over ~18 years and is independently associated with cardiovascular mortality, stroke, atrial fibrillation, treatment-resistant hypertension, and metabolic deterioration Young 2008. Daytime sleepiness and cognitive impairment are the felt costs; the silent costs are progressive cardiovascular and metabolic damage and increased motor-vehicle accident risk. Prevalence of clinically significant OSA is ~14% of men and ~5% of women in middle age, rising with obesity, and the majority of cases are undiagnosed Peppard 2013.

Payoff

For the typical SURMOUNT-OSA participant (severe OSA, BMI 39): one year on full-dose tirzepatide produces a ~20% body weight loss, a ~50% chance of AHI dropping below mild-OSA thresholds, ~7–9 mmHg systolic BP reduction, substantial reductions in inflammation, and meaningful improvement in patient-reported sleep impairment. In the PAP-experienced cohort, daytime sleepiness improvements were on top of whatever PAP was already providing. Whether the AHI reduction translates into the same cardiovascular event reduction that CPAP failed to deliver in SAVE is unproven — the SELECT trial of semaglutide in obesity without diabetes did show a ~20% reduction in MACE, suggesting GLP-1-axis agents have CV benefit that is mechanism-distinct from CPAP Lincoff 2023. SURPASS-CVOT for tirzepatide is ongoing.

Practicalities

US list price: ~$1,000–1,350/month (Zepbound) at maintenance doses. Insurance coverage has been the binding constraint: many commercial plans excluded GLP-1 agents for obesity; Medicare statutorily cannot cover weight-loss drugs. The OSA indication potentially changes coverage — an OSA-coded prescription is a medical-necessity claim, not a cosmetic one, and several large payers and Medicare have signalled coverage for the OSA indication. Out-of-pocket reality without coverage: ~$12,000–16,000/year. With manufacturer savings cards (commercial insurance only), as low as $25/month, but limited duration. Supply has been intermittent since 2023; shortage status has eased but is not fully resolved.

Practical logistics: weekly self-injection (pen autoinjector), refrigerated storage, dose titration over months, monthly visits during titration. Common adjustments: anti-emetics during titration, hydration counseling, screening for biliary symptoms, baseline calcitonin if any thyroid risk concerns.

Audience

The trial population was adults aged 18–75, mean ~50, ~70% male, BMI ≥30 (mean ~39), with moderate-to-severe OSA (AHI ≥15). Effects on milder OSA, lower BMI, older adults, and non-obese adults are unstudied. The FDA label is restricted to adults with obesity and moderate-to-severe OSA. The effect generalizes plausibly down to BMI ~30 and across the demographic spread of trial participants. There is no signal of sex-differential effect on AHI; women were under-represented in the trials (consistent with epidemiology).

Misconceptions

Three common ones. First, that tirzepatide is "for OSA" in any direct sense — it is a weight-loss agent that, because weight loss treats obesity-driven OSA, also treats the OSA. The substrate-specific effect goes away in lean OSA, which is a different disease. Second, that it replaces CPAP — SURMOUNT-OSA did not test that, the FDA label does not say that, and CPAP remains a more direct, more rapid, and far cheaper way to lower AHI for the patient who tolerates it. Third, that it is a course of treatment — discontinuation reliably regains weight and recurs OSA; this is indefinite therapy.

Credibility range

Optimist case

This is one of the more straightforward optimist cases in modern sleep medicine. The pivotal trial is two RCTs with consistent, large effects across primary and secondary endpoints, published in NEJM, leading directly to an FDA approval. The mechanism — weight loss → reduced upper airway fat → reduced collapsibility → reduced AHI — is well-established from independent imaging and bariatric-surgery literatures, with replication across decades. Cardiovascular spillover from GLP-1-axis agents is the strongest news in cardiometabolic medicine of the past five years; SELECT showed mortality reduction in obesity without diabetes, and tirzepatide outperforms semaglutide on weight. Adherence is dramatically better than CPAP (a weekly injection vs nightly mask). Even partial responders (~50% with full disease resolution criteria; near-universal with substantial AHI improvement) get major weight, BP, and inflammation benefits. For the large cohort of OSA patients who refuse, fail, or partially adhere to CPAP, this is plausibly the first treatment that actually changes their cardiometabolic trajectory.

Skeptic case

SURMOUNT-OSA established AHI reduction, not cardiovascular event reduction. CPAP also reliably lowers AHI in trials and has so far failed to reduce hard CV events in RCTs (SAVE); the assumption that AHI is a valid surrogate is contested. The trials were 52 weeks — the longest signal we have, but short relative to OSA's natural history (decades). Discontinuation is the elephant: this is permanent therapy whose effects fully reverse on stopping, at a real cost of ~$12k/year and ongoing GI burden. Long-term safety beyond ~5 years is unknown. Cost-effectiveness is unfavorable against CPAP for patients who can tolerate CPAP, and access is gated by insurance with significant equity concerns. The "addresses root cause" framing flatters the drug — it addresses obesity, which causes the OSA. Direct lifestyle weight loss, bariatric surgery, and CPAP all remain on the table; the right comparator question (drug vs surgery vs CPAP combinations, head-to-head) has not been asked.

Author's call

Strong, evidence-backed advance for a specific population: adults with obesity-driven moderate-to-severe OSA who cannot or will not tolerate CPAP, or who would benefit from the weight-loss / cardiometabolic spillover. Not a CPAP replacement for the patient who uses CPAP well; not a magic bullet for non-obese OSA; not a course of treatment. Evidence rates 4/5 (two pivotal RCTs, FDA approval, but new indication and surrogate endpoint). Real impact on sleep quality, energy, weight, blood pressure, and inflammation; plausible but unproven CV-event reduction. Cost and lifelong-therapy implications are non-trivial and ride alongside the benefits.

Stakeholder + incentive map

Eli Lilly — manufacturer; commercial incentive massive. The OSA indication broadens insured access; expect heavy promotion to sleep medicine.
Sleep medicine and pulmonology societies (AASM, ATS) — guidelines historically PAP-centric; pharmacologic options newly relevant. Updated guidance in progress as of 2025.
CPAP device manufacturers (ResMed, Philips) — defensive counter-positioning; emphasising PAP's hard outcome data and adherence improvements with newer interfaces.
Bariatric surgery community — competing weight-loss intervention; sees GLP-1/GIP agents as both threat and triage tool.
Payers and PBMs — face large cost exposure if OSA-coded prescribing scales; expect aggressive utilization management.
Patient advocacy — strongly pro, especially among CPAP-intolerant patients.

Population variability

BMI and baseline weight: AHI response tracks weight loss; lower baseline BMI likely smaller absolute AHI effect. Below BMI 30 is unstudied.
Sex: No clear sex-differential signal on AHI. Women under-represented in trials.
Age: Trials ran 18–75; older adults included. Polypharmacy and frailty raise practical concerns; trial data thin above ~70.
Race/ethnicity: Limited subgroup analyses; the SURMOUNT programme as a whole is predominantly white-Western; effect on craniofacial-anatomy-driven OSA (more prevalent in some East Asian populations) is theoretically weaker because the obesity lever is smaller.
Diabetes status: Effective with or without T2D; combined T2D + OSA likely the highest-benefit cohort due to converging cardiometabolic gains.
OSA severity: Trial enrolled AHI ≥15. Effect on mild OSA is unstudied; mild OSA also has weaker CV-outcome evidence overall.
OSA phenotype: Strongest mechanistic case for obesity-dominant pharyngeal-crowding phenotype. Patients whose OSA is primarily craniofacial, neuromuscular, or positional may respond less.

Knowledge gaps

Cardiovascular event reduction (MACE) in OSA specifically — SURPASS-CVOT in T2D is ongoing; no OSA-cohort CV-outcome trial exists yet.
Long-term (>2 years) safety and durability of OSA response.
Head-to-head with CPAP, mandibular advancement, hypoglossal-nerve stimulation, and bariatric surgery.
Combination strategies: does adding tirzepatide to CPAP reduce CPAP discontinuation, or enable PAP-pressure de-escalation?
Effect in non-obese OSA (the lean OSA phenotype) — likely none, but untested.
Cost-effectiveness from a payer / public-health perspective compared with CPAP.
Discontinuation strategy: is there a maintenance dose lower than 10/15 mg that preserves AHI benefit at lower cost and side-effect burden?
Pediatric OSA — not studied; not currently indicated.

The brief named four consequences (AHI, weight, daytime sleepiness, downstream cardiovascular risk); the article and meta cover all four. No silent narrowing. The brief said OSA-with-obesity; the entry inherits that scoping rather than trying to cover the lean-OSA phenotype, where the drug's mechanism (weight loss) doesn't apply.

Notes on hard calls during the write:

Positioning vs CPAP. The drug has not been tested head-to-head against CPAP, and the article says so explicitly. Strong temptation to frame this as a CPAP replacement given commercial framing in the press; resisted. The honest framing is "first medication for OSA; not a replacement for the patient who tolerates CPAP". This shows up in alternatives, misconceptions, and the dek.
Cardiovascular framing. SURMOUNT-OSA only reported AHI, BP, hsCRP, and weight — not MACE. The article notes the absence of an OSA-cohort cardiovascular outcomes trial and points at SELECT (semaglutide in obesity) and the Sattar 2022 meta as the strongest indirect evidence. Resisted the temptation to claim CV-event reduction.
Discontinuation. Treated as a first-class topic, not a footnote — both in failure-modes and again in misconceptions. The most common patient/clinician misread is treating the drug as a course.
Cost burden rated 4. List price ($12–16k/year) puts it in the 5 anchor ("prohibitive for most people"), but with the new OSA indication driving real insurance access, lived experience varies enough that 4 is the honest call. Could move to 5 if coverage stalls.
Mood rated 2. Borderline 1/2. The relational and sleep-restoration knock-on for mood (partner not lying awake, less daytime irritability) is real but indirect; no direct mood endpoint in SURMOUNT-OSA. 2 reads honest; 1 would understate.
Status set to live. Evidence base is strong, FDA-approved indication, all dimensions backed by the dossier.

Excluded with rationale:

Pediatric OSA — not studied, not on label, different anatomic substrate.
Lean OSA — mechanism doesn't apply; would mislead.
Non-tirzepatide GLP-1 agonists (semaglutide, liraglutide) for OSA — referenced only as comparators. Each warrants its own entry if and when the OSA evidence arrives.
Detailed bariatric-surgery comparison — touched in alternatives; warrants its own entry rather than a section here.
Older pharmacologic candidates for OSA (atomoxetine + oxybutynin, AD109/aroxybutynin) — passed over in favour of focusing on what's FDA-approved.

Future-link candidates (when the entries exist):

A CPAP / PAP-therapy entry — the natural anchor for the alternatives section's first half.
A GLP-1 / GIP drug class entry covering the broader weight-loss landscape.
A bariatric-surgery-for-OSA entry.
An OSA-diagnosis entry covering the at-home vs in-lab sleep study, central vs obstructive apnea, and screening.
An ApoB entry and an hsCRP entry, both referenced in out-of-scope.
A mandibular-advancement-device entry.
A hypoglossal-nerve-stimulation (Inspire) entry.

Population variability worth flagging to a reviewer: women were under-represented in SURMOUNT-OSA (~30%), consistent with OSA epidemiology; effect estimates in women are based on smaller subgroups but show the same direction. Trial population was predominantly white-Western; the dossier flags this as a generalisability gap rather than restricting the audience tag, since obesity-driven OSA pathophysiology is plausibly the same across populations.